Lyophilized ARA-290 (16mg) research peptide vial, verified purity

ARA-290 (16mg)

Technische Spezifikationen

Reinheit (HPLC)≥98% (HPLC)
CAS-Nummer1208243-50-8
FormWhite lyophilized powder
Lagerung-20°C
SequenzpGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser
Molekulargewicht1,257.4 g/mol
SalzformAcetate
LöslichkeitSoluble in water
PeptideSKU: PEPTIDE-1598C9

ARA-290 (16mg)

150,00 EUR
Auf Lager

EUR-Listenpreis · HU, SK, CZ, PL

  • Eurozone (EUR)150,00 EUR
  • Ungarn (HU)150,00 EUR
    60 000 Ft
  • Slowakei (SK)150,00 EUR
  • Tschechien (CZ)150,00 EUR
    3 750 Kč
  • Polen (PL)150,00 EUR
    637,50 zł

Gleicher EUR-Listenpreis für Lieferung nach Ungarn, Slowakei, Tschechien und Polen. Abrechnung in EUR.

HUF/CZK/PLN sind indikativ aus EUR umgerechnet; die Slowakei nutzt EUR. Kurse annähernd. Abrechnung in EUR.

≥98% (HPLC) Reinheit
HPLC/MS verifiziert
Kostenloser EU-Versand

ARA-290 (Cibinetid) — 11-amminosäurisches Peptid, das den Innate-Repair-Heterorezeptor aktiviert; in der Literatur in Modellen zu Neuropathie und Gewebeheilung. Nur RUO — ausschließlich für Laborforschung; nicht zum menschlichen Verzehr.

1
Peptid-Rekonstitutionsrechner

Ausschließlich für Laborforschung.
Nicht für den menschlichen Verzehr, tierärztliche oder diagnostische Zwecke.

Research Database

From the Peptide Explorer

An 11-amino-acid peptide derived from the tissue-protective domain of erythropoietin. It selectively binds the heterodimeric innate repair receptor (EPOR/βcR) expressed on injured tissue—triggering the cytoprotective and anti-inflammatory arm of EPO signaling without stimulating hematopoiesis via the classic EPOR homodimer.

NeuroprotectionImmune ModulationHealing & Regeneration

Key Mechanisms

  • Innate repair receptor (EPOR/βcR) agonism
  • JAK2-STAT signaling in injured tissue
  • Reduction of pro-inflammatory cytokines (TNF-α, IL-6)
  • Endothelial protection against ischemic injury
  • Promotion of peripheral nerve regeneration

Primary Research Areas

  • Sarcoidosis-associated small-fiber neuropathy
  • Diabetic peripheral neuropathy
  • Ischemic injury and reperfusion
  • Chronic inflammation research

Key Research Findings

  • Improved corneal nerve fibre density and pain scores in sarcoid small-fiber neuropathy (Brines et al., Mol Med 2014)
  • Reduced neuropathic pain in phase-2 diabetic neuropathy trial (Dahan et al., 2013)
  • Tissue-protective activity without altering haematocrit in rodent and primate models

Research Overview

An 11-amino-acid peptide derived from the tissue-protective domain of erythropoietin. It selectively binds the heterodimeric innate repair receptor (EPOR/βcR) expressed on injured tissue—triggering the cytoprotective and anti-inflammatory arm of EPO signaling without stimulating hematopoiesis via the classic EPOR homodimer.

Origin: Synthetic peptide derived from the aqueous face of helix B of erythropoietin (EPO); engineered to retain tissue-protective activity without hematopoiesis

Mechanism of Action

  • Innate repair receptor (EPOR/βcR) agonism
  • JAK2-STAT signaling in injured tissue
  • Reduction of pro-inflammatory cytokines (TNF-α, IL-6)
  • Endothelial protection against ischemic injury
  • Promotion of peripheral nerve regeneration

Primary Research Areas

  • Sarcoidosis-associated small-fiber neuropathy
  • Diabetic peripheral neuropathy
  • Ischemic injury and reperfusion
  • Chronic inflammation research

Key Published Findings

  • Improved corneal nerve fibre density and pain scores in sarcoid small-fiber neuropathy (Brines et al., Mol Med 2014)
  • Reduced neuropathic pain in phase-2 diabetic neuropathy trial (Dahan et al., 2013)
  • Tissue-protective activity without altering haematocrit in rodent and primate models

Research Protocol

Commonly studied routes: Subcutaneous. Reconstitute with bacteriostatic water. Consult published literature for dose ranges; use our Peptide Calculator for volumetric preparation.

Storage

-20°C lyophilized

Important Notice

ARA-290 (16mg) is supplied for laboratory research use only (RUO). Not for human or veterinary use, diagnostics, or therapeutics.

Forschungsspezifikationen

Synthesized for strict analytical consistency. Verified via HPLC/MS.Qualitätsstandards ansehen

Sequenz
pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser
Massenspektrometrie
Identität bestätigt

Handhabung & Lagerung

  • Store lyophilized at -20°C
  • Protect from light and moisture
  • Use sterile bacteriostatic water for reconstitution
  • Minimize freeze-thaw cycles
  • Solubility: Soluble in water

Häufige Fragen

What is ARA-290 (16mg)?
ARA-290 (16mg) is a research compound in the Peptides category. Synthetic peptide derived from the aqueous face of helix B of erythropoietin (EPO); engineered to retain tissue-protective activity without hematopoiesis
Is ARA-290 (16mg) intended for human consumption?
No. All products on peptide limited are supplied strictly for laboratory and research use only (RUO). They are not intended for human or veterinary use, diagnostics, or therapeutics.
How do you verify purity and identity?
Batches are verified using analytical methods such as HPLC and Mass Spectrometry to confirm identity and assess purity. We publish COA documentation when available and can provide batch documentation on request.
How should ARA-290 (16mg) be stored?
Store lyophilized material sealed, protected from light and moisture, at -20°C for long-term stability. After reconstitution, minimize freeze-thaw cycles and use sterile handling protocols.
Do you provide a Certificate of Analysis (COA)?
COAs are available for many batches. If a COA link is not shown on this page, please contact support to request the latest documentation for your batch.
What purity is ARA-290 (16mg)?
This product is supplied at ≥98% (HPLC) purity as determined by HPLC analysis. Identity is confirmed via Mass Spectrometry (MS).

Verified Research Reviews

0.0 / 5.0(0 total)
No research reviews submitted for this compound yet.

Log Research Findings

Ähnliche Research-Verbindungen